DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for otitis media with effusion — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOtitis media with effusion maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for otitis media with effusion is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
A 1998 meta-analysis of research published between 1980 and 1997 examined pharmacologic treatment of otitis media with effusion in children aged three months to 12 years. The analysis compared antibiotics, antihistamines, decongestants, and combinations of these agents against no treatment. Pharmacologic treatment was statistically significant in resolving effusion compared to no treatment (P=0.0017), but the effect size was weak (R=0.07). The hypothesis that untreated children would show equal resolution to treated children was rejected.
A 1989 critical review of the literature, including the authors' own randomised double-blinded studies, found no support for the widespread use of drugs for otitis media with effusion. The review stated that neither mucolytic agents, decongestants, nor antihistamines had any favourable effect on the course of the disease. Success with steroids or antibiotic agents in selected cases was described as very limited.
A 2014 review noted that acute otitis media and otitis media with effusion remain common childhood disorders, a source of significant morbidity, and a leading cause of antibiotic prescription in primary health care. The review stated that although effective treatments are available, some shortcomings remain, and that recent discoveries in aetiology and pathogenesis have led to investigation of novel treatments. A 1989 review of immunological characteristics of middle ear effusion reported detection of immunocytes and soluble substances including immunoglobulin, immune complex, complement, interferon, tumour necrosis factor, and immunosuppressive substances, but did not report any treatment outcomes.
What is still missing is a pharmacologic intervention with a clinically meaningful effect size. The weak effect of existing drugs, the very limited success of steroids and antibiotics, and the lack of benefit from mucolytics, decongestants, and antihistamines mean that no drug regimen has been shown to reliably resolve effusion better than watchful waiting. Adequately powered trials that stratify patients by age, duration of effusion, and underlying immune or inflammatory profile are lacking, as is funding for such trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Infection and Drug Resistance · 2014 · 183 citations · open access
Update on otitis media – prevention and treatment
AbstractAcute otitis media and otitis media with effusion are common childhood disorders, a source of significant morbidity, and a leading cause of antibiotic prescription in primary health care. Although effective treatments are available, some shortcomings remain, and thus better treatments would be welcome. Recent discoveries within the field of otitis media research relating to its etiology and pathogenesis have led to further investigation aimed at developing novel treatments. This article provides a review of the latest evidence relating to the understanding of acute otitis media and otitis media with effusion, current treatment strategies, their limitations, new areas of research, and novel strategies for treatment.
Worldviews on Evidence-based Nursing presents the archives of Online Journal of Knowledge Synthesis for Nursing · 1998 · 9 citations
A Comparison of the Effectiveness of Pharmacologic Treatment of Otitis Media with Effusion in Children: Integrative and Meta‐Analysis
AbstractThe treatment of otitis media with effusion is controversial and has inconsistent variations of pharmacotherapeutic practices. Current pharmacologic practices include use of antibiotics, antihistamine and/or decongestants, or a combination of antibiotics with antihistamine and/or decongestants. The effectiveness of these treatment protocols was examined through an integrative and meta-analysis of published research. Data was collected from research published over a 17 year period from 1980 to 1997. The hypothesis is that children, ages three months to 12 years, with otitis media with effusion who are untreated will demonstrate successful resolution of effusion equal to those treated with pharmacologic agents (P < 0.05). The integrative and meta-analytic results reject this hypothesis, as pharmacologic treatment is statistically significant in its resolution when compared to no treatment (P=0.0017). However, there is a weak effect size (R=0.07).
Gibt es eine medikamentöse Therapie beim Sero-Mucotympanon?*
AbstractA critical review of the literature (including the authors' own randomized double-blinded studies) does not support the widespread use of drugs for treatment of otitis media with effusion (secretory otitis media).--Neither mucolytic agents, nor decongestants, nor antihistamines have any favourable effect on the course of the disease. Success with steroids or antibiotic agents in selected cases is very limited.
Immunological Characteristics of Middle Ear Effusion
AbstractIn middle ear effusion of otitis media with effusion, immunocytes and various soluble substances (immunoglobulin, immune complex, complement, interferon, tumor necrosis factor, immunosuppressive substance, immunosuppressive acidic protein) related to immune response are detected. We reviewed the literature on these immune soluble factors with respect to their effects on otitis media with effusion.
Current Opinion in Otolaryngology & Head & Neck Surgery · 1994 · 0 citations
Otitis media
AbstractOtitis media as a clinical entity has received significant press recently both in the lay and professional literature. Despite recent debate regarding management protocols, significant basic and clinical research continues in an attempt to limit the untoward effects of this very common pathologic process. This review directs attention to newer concepts regarding both the pathobiology of otitis media and the pharmacotherapy available for management.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
